Literature DB >> 9811440

A comparison between clenbuterol, salbutamol and terbutaline in relation to receptor binding and in vitro relaxation of equine tracheal muscle.

K Törneke1, C Ingvast Larsson, L E Appelgren.   

Abstract

Beta2-adrenoceptor agonists are used as bronchodilators in both humans and horses. Of these drugs, clenbuterol is the one most frequently used when treating chronic obstructive pulmonary disease in the horse, while salbutamol and terbutaline are used in the treatment of human asthma. Little is known of the properties of the latter two drugs in equine medicine. We have compared salbutamol and terbutaline with clenbuterol in relation to their ability to relax muscle strips from equine tracheal muscle, precontracted with 40 nM carbachol, in tissue chambers. The affinities of these drugs to the beta2-adrenoceptors in homogenates of the same muscle tissue were also examined. These experiments were performed with radioligand binding studies using the very potent beta-adrenoceptor antagonist 125I-cyanopindolol. The three drugs were almost equipotent in relaxing the muscle strips. The EC50-values for salbutamol, terbutaline and clenbuterol were 5.6, 13.8 and 2.1 nM, respectively, and all three drugs relaxed the preparations completely. In the competitive binding study, however, the Kd-value of clenbuterol was much lower (24 nM) than that of salbutamol and terbutaline (1100 nM and 3900 nM, respectively). The amount of receptors bound at the EC50-value of clenbuterol was 8% compared to less than 1% for salbutamol and terbutaline. This indicates a lower intrinsic efficacy of clenbuterol than of the other two drugs. The beta-adrenoceptor density was 45 +/- 14.3 fmol/mg protein (mean +/- SD) and the Kd-value of 125I-cyanopindolol was 11.4 +/- 3.3 pM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811440     DOI: 10.1046/j.1365-2885.1998.00156.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  8 in total

1.  Reactivity of equine airways--a study on precision-cut lung slices.

Authors:  J Vietmeier; F Niedorf; W Bäumer; C Martin; E Deegen; B Ohnesorge; M Kietzmann
Journal:  Vet Res Commun       Date:  2007-01-24       Impact factor: 2.459

2.  Ligand-dependent perturbation of the conformational ensemble for the GPCR β2 adrenergic receptor revealed by HDX.

Authors:  Graham M West; Ellen Y T Chien; Vsevolod Katritch; Jovylyn Gatchalian; Michael J Chalmers; Raymond C Stevens; Patrick R Griffin
Journal:  Structure       Date:  2011-09-01       Impact factor: 5.006

3.  Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease.

Authors:  Benjamin L Farah; Lauran Madden; Songtao Li; Sierra Nance; Andrew Bird; Nenad Bursac; Paul M Yen; Sarah P Young; Dwight D Koeberl
Journal:  FASEB J       Date:  2014-01-21       Impact factor: 5.191

4.  Beta-adrenoceptors in equine trachea and heart.

Authors:  K Töneke
Journal:  Vet Res Commun       Date:  1999-01       Impact factor: 2.459

5.  Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease.

Authors:  Songtao Li; Baodong Sun; Mats I Nilsson; Andrew Bird; Mark A Tarnopolsky; Beth L Thurberg; Deeksha Bali; Dwight D Koeberl
Journal:  FASEB J       Date:  2012-09-19       Impact factor: 5.191

6.  DIRECT-ID: An automated method to identify and quantify conformational variations--application to β2 -adrenergic GPCR.

Authors:  Sirish Kaushik Lakkaraju; Justin A Lemkul; Jing Huang; Alexander D MacKerell
Journal:  J Comput Chem       Date:  2015-11-12       Impact factor: 3.376

7.  Selection and Identification of Novel Aptamers Specific for Clenbuterol Based on ssDNA Library Immobilized SELEX and Gold Nanoparticles Biosensor.

Authors:  Xixia Liu; Qi Lu; Sirui Chen; Fang Wang; Jianjun Hou; Zhenlin Xu; Chen Meng; Tianyuan Hu; Yaoyao Hou
Journal:  Molecules       Date:  2018-09-13       Impact factor: 4.411

8.  Postnatal β2 adrenergic treatment improves insulin sensitivity in lambs with IUGR but not persistent defects in pancreatic islets or skeletal muscle.

Authors:  Dustin T Yates; Leticia E Camacho; Amy C Kelly; Leah V Steyn; Melissa A Davis; Andrew T Antolic; Miranda J Anderson; Ravi Goyal; Ronald E Allen; Klearchos K Papas; William W Hay; Sean W Limesand
Journal:  J Physiol       Date:  2019-11-29       Impact factor: 5.182

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.